Abstract
The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Current Enzyme Inhibition
Title: Breast Cancer Chemoprevention: Current Perspectives
Volume: 5 Issue: 4
Author(s): Takeru Oyama, Yumiko Yasui and Takuji Tanaka
Affiliation:
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Abstract: The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Export Options
About this article
Cite this article as:
Oyama Takeru, Yasui Yumiko and Tanaka Takuji, Breast Cancer Chemoprevention: Current Perspectives, Current Enzyme Inhibition 2009; 5 (4) . https://dx.doi.org/10.2174/157340809789630271
DOI https://dx.doi.org/10.2174/157340809789630271 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Design of Lanthanide Complex Probes for Highly Sensitive Time-Resolved Fluorometric Detection Methods and Its Application to Biochemical, Environmental and Clinical Analyses
Current Analytical Chemistry Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of Isolated Isoflavones Intake on Health
Current Medicinal Chemistry Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry A Review on Anti-urease Potential of Coumarins
Current Drug Targets Atomic Force Microscopy and Anodic Porous Allumina of Nucleic Acid Programmable Protein Arrays
Recent Patents on Biotechnology Near-Infrared Dyes: Probe Development and Applications in Optical Molecular Imaging
Current Organic Synthesis ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design The Ultrasonographic Diagnosis of Polycystic Ovary Syndrome
Current Medical Imaging Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design Subject Index to Volume 10
Current Pharmaceutical Design The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Protein Misfolding in Conformational Disorders: Rescue of Folding Defects and Chemical Chaperoning
Mini-Reviews in Medicinal Chemistry Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Editorial [Hot Topic: MicroRNA Regulation and its Biological Significance in Personalized Medicine and Aging (Guest Editor: Eugenia Wang)]
Current Genomics Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Defensive Role of Plant-Derived Secondary Metabolites: Indole and Its’ Derivatives
Current Biotechnology 18F-fluoro-deoxy-D-glucose PET/CT in Establishing the Relationship Between the Metabolic Activity of Aorta and Iliac Artery Aneurysms in Cancer Patients
Current Medical Imaging